On July 10, researcher Lee Dal-mi from SK Securities stated, "The company’s second-quarter performance peaked, and although sales growth may slow down entering the third quarter, which is an off-season, solid results are still expected. Continuous new product launches of COVID-19 diagnostic kits and increased demand due to the second wave of COVID-19 are expected to sustain growth until 2021." She set Seegene’s target price at 200,000 KRW.
Over the past five days, individual investors have net sold 11,916 shares of Seegene, while foreigners and institutions have net bought 53,994 shares and net sold 26,166 shares, respectively.

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

